News archive
Showing 692 results
August 2014
-
Media Release
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)- On all-cause mortality, LCZ696 doubled the effect… -
Media Release
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
-
Media Release
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF-- PARADIGM-HF is the largest heart… -
Media Release
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
July 2014
-
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1]- A statistically… -
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL)- The filing was submitted by the University… -
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
June 2014
-
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2)Basal cell carcinoma is the most common form of skin… -
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma